⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

February 1, 2026The Lancet MicrobeOpen Access

Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study

Onyema Ogbuagu Aditya Gaur James H McMahon Linda Gorgos Javier O Morales-Ramirez Kimberly Workowski Jason Brunetta Kwad Mponponsuo Sean E Collins Laurie A VanderVeen Nan Zhang Hailin Huang Fei Gao Joseph Eron

View Full Paper

Ask AI

Bookmark

Share

Key Points

The findings indicate positive efficacy and safety outcomes for lenacapavir, teropavimab, and zinlirvimab.
Primary outcomes were assessed at week 26 in this phase 2 randomized controlled trial.
Participants received one of the three active medications over a specified treatment period.
These results may support the future use of these agents in clinical practice, warranting further research.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Multicentre trial assesses efficacy and safety of three treatments, suggesting potential benefits for managing conditions.

Abstract

Gilead Sciences.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ogbuagu et al. (2026) studied this question.

synapsesocial.com/papers/69a761c8c6e9836116a2fdc2 https://doi.org/10.1016/j.lanmic.2025.101283

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Association of ART regimen and adherence to viral suppression: an observational study of a clinical population of people with HIVObservational Study · 2024 · 32 citations
2A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapySystematic Review · 2014 · 165 citations
3Long-acting injectable antiretroviral therapy for HIV-1 infection in adults2024 · 3 citations
4Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 WeeksLate-Phase Clinical Trial · 2020 · 90 citations
5Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countriesOriginal Research · 2020 · 79 citations
6Patient preferences for long-acting HIV treatment: a preference heterogeneity assessmentOriginal Research · 2025 · 10 citations
7Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionOriginal Research · 2022 · 353 citations
8Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infectionCross-Sectional Study · 2013 · 357 citations
9Host and environmental factors associated with upper respiratory tract mycobiota in healthy individuals: a cross-sectional observational studyThe Lancet Microbe · 2026
10Importance of faecal sample collection in prospective cohort studies to evaluate the effect of the gut microbiome on cancer developmentThe Lancet Microbe · 2026

More from The Lancet Microbe

More from Yale University

More from University of North Carolina at Chapel Hill

More from Emory University

More from Monash University

More from St. Jude Children's Research Hospital

More from The Alfred Hospital

More from Gilead Sciences (United States)

More from Monash Alfred Psychiatry Research centre

More from Maple Leaf Medical Clinic

More from Clinical Research Puerto Rico